Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
180 participants
OBSERVATIONAL
2020-01-01
2022-06-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
* 38% of patients will be cured with a 2nd line including an autologous haematopoietic cell transplantation for those under 65 years.
* for older patients who are not eligible for a autograft: only 70% of patients will be able to receive 2nd line treatment with rates response less than 50%.
* the survival rate in patients receiving 3rd line treatment or more is 15% at 2 years. Actually, no standard of chemotherapy is offered to relapsed or refractory patients after 2 therapeutic lines. Subsequent lines lead to hospitalizations for infectious complications or transfusions without clear clinical benefit with often an impacted quality of life.
Palliative care is rarely offered as part of the treatment overall load.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Refractory Diffuse Large B-cell Lymphoma
NCT03664336
The Potential of Patient-reported Outcome Measures in Detection of Relapse in Diffuse Large B-cell Lymphoma
NCT04695366
A Phase I/II Study of Diffuse Large B-cell Lymphoma
NCT04856137
Prognostic Value of Clinical and Biological Factors in Patients With Refractory/Relapsed Diffuse Large B-cell Lymphoma
NCT01369784
Multicenter Retrospective Observational Study of Relapsed Diffuse Large B-Cell Lymphoma Presenting As Indolent Lymphoma
NCT06822829
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
population
The population includes adult patients.
* Patients died from refractory or relapsed diffuse large-cell lymphoma.
* Patients \<65 years of age eligible for an autologous transplant should have relapsed after the autologous transplant.
* Patients \>65 years of age or not eligible after an autologous transplant must have received at least one RCHOP-type treatment line (2 cycles).
prognostic assessment
determination of a prognostic score with 3 clinical and 5 biological parameters.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
prognostic assessment
determination of a prognostic score with 3 clinical and 5 biological parameters.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* died of diffuse large B cell lymphoma
* Refractory or relapsing after 2 treatment lines for young patients (RCHOP then recovery with platinum salts and autograft) and one line for elderly patients (RCHOP)
Exclusion Criteria
* solid tumor treated less than 5 years ago with the exception of skin carcinoma or carcinoma in situ of the uterine cervix treated locally
* inclusion in a therapeutic trial
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Weprom
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Katell LE DU, MD
Role: STUDY_DIRECTOR
Weprom
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Clinique Victor Hugo / Centre Jean Bernard
Le Mans, , France
Centre d'Oncologie de Gentilly
Nancy, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Katell LE DU, MD
Role: CONTACT
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
WP-2019-02
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.